Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)513-514
Number of pages2
JournalBJU International
Volume109
Issue number4
DOIs
StatePublished - Feb 1 2012

ASJC Scopus subject areas

  • Urology

Cite this